NCT01605474

Brief Summary

This study examines whether outpatient pre-induction cervical ripening improves patient satisfaction and is safe and effective.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
800

participants targeted

Target at P75+ for not_applicable pregnancy

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 18, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 25, 2012

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
Last Updated

May 25, 2012

Status Verified

May 1, 2012

Enrollment Period

2.2 years

First QC Date

May 18, 2012

Last Update Submit

May 23, 2012

Conditions

Keywords

foley catheterfoley bulbinduction of laborlabor

Outcome Measures

Primary Outcomes (1)

  • Cesarean section rate

    Cesarean delivery rate between groups

    2 years

Secondary Outcomes (3)

  • Patient satisfaction (Pain /discomfort)

    2 year

  • Apgar scores

    2 years

  • NICU admissions

    2 years

Study Arms (2)

Outpatient Cervical Ripening

ACTIVE COMPARATOR

Patients who are randomized to this arm will be allowed discharged home for 12 hours after fetal status is assessed and noted to be reassuring with the foley bulb in place. They will return sooner if they experience rupture of membranes or enter active labor or if the foley bulb falls out.

Other: Patient discharged home after foley bulb placement.

Inpatient Cervical Ripening

NO INTERVENTION

In this arm, the fetus will be assessed and a foley bulb placed but these patients will be kept in the hospital.

Other: Inpatient

Interventions

The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.

Also known as: Foley bulb (16 French)
Outpatient Cervical Ripening

The patients will not be discharged home after assessment and placement of the foley catheter.

Also known as: Foley Bulb (16 French)
Inpatient Cervical Ripening

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • term pregnancy
  • singleton gestation
  • cephalic presentation
  • scheduled for an induction of labor (acceptable conditions include gestational diabetes, chronic hypertension)

You may not qualify if:

  • placenta previa and/or accreta
  • low lying placenta
  • undiagnosed vaginal bleeding
  • preeclampsia
  • fetal anomaly
  • intrauterine growth restriction
  • RH isoimmunization
  • fetal demise
  • rupture of membranes
  • maternal heart disease
  • known latex allergy
  • active genital herpes infection
  • previous uterine surgery
  • limited access to a telephone
  • excessive distance from the hospital, and/or
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States

RECRUITING

Related Publications (1)

  • Sciscione AC, Muench M, Pollock M, Jenkins TM, Tildon-Burton J, Colmorgen GH. Transcervical Foley catheter for preinduction cervical ripening in an outpatient versus inpatient setting. Obstet Gynecol. 2001 Nov;98(5 Pt 1):751-6. doi: 10.1016/s0029-7844(01)01579-4.

    PMID: 11704164BACKGROUND

MeSH Terms

Interventions

Inosine Monophosphate

Intervention Hierarchy (Ancestors)

Inosine NucleotidesPurine NucleotidesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsNucleotidesNucleic Acids, Nucleotides, and NucleosidesRibonucleotides

Study Officials

  • Tania Esaoff, MD

    Cedars-Sinai Medical Center, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Tania F Esakoff, MD

CONTACT

Gregory W Lau, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Fellow, Maternal Fetal Medicine

Study Record Dates

First Submitted

May 18, 2012

First Posted

May 25, 2012

Study Start

April 1, 2012

Primary Completion

July 1, 2014

Last Updated

May 25, 2012

Record last verified: 2012-05

Locations